Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. McGinn, CJ; Zalupski, MM
   Combined-modality therapy in pancreatic cancer: Current status and future directions
   CANCER JOURNAL
   
   C.J. McGinn e M.M. Zalupski, "Combined-modality therapy in pancreatic cancer: Current status and future directions", CANCER J, 7(4), 2001, pp. 338-348
2. van de Wijgert, J; Fullem, A; Kelly, C; Mehendale, S; Rugpao, S; Kumwenda, N; Chirenje, Z; Joshi, S; Taha, T; Padian, N; Bollinger, R; Nelson, K
   Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites
   JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
   
   J. van de Wijgert et al., "Phase 1 trial of the topical microbicide BufferGel: Safety results from four international sites", J ACQ IMM D, 26(1), 2001, pp. 21-27
3. Sawai, N; Zhou, S; Vanin, EF; Houghton, P; Brent, TP; Sorrentino, BP
   Protection and in vivo selection of hematopoietic stem cells using temozolomide, O-6-benzylguanine, and an alkyltransferase-expressing retroviral vector
   MOLECULAR THERAPY
   
   N. Sawai et al., "Protection and in vivo selection of hematopoietic stem cells using temozolomide, O-6-benzylguanine, and an alkyltransferase-expressing retroviral vector", MOL THER, 3(1), 2001, pp. 78-87
4. June, CH
   Can't get any help? New approaches for adoptive immunotherapy of cancer
   JOURNAL OF IMMUNOTHERAPY
   
   C.H. June, "Can't get any help? New approaches for adoptive immunotherapy of cancer", J IMMUNOTH, 24(5), 2001, pp. 389-391
5. Bodell, WJ; Giannini, DD; Hassenbusch, S; Levin, VA
   Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors
   NEURO-ONCOLOGY
   
   W.J. Bodell et al., "Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors", NEURO-ONCOL, 3(4), 2001, pp. 241-245
6. Gunzburg, WH; Salmons, B
   Novel clinical strategies for the treatment of pancreatic carcinoma
   TRENDS IN MOLECULAR MEDICINE
   
   W.H. Gunzburg e B. Salmons, "Novel clinical strategies for the treatment of pancreatic carcinoma", TRENDS MO M, 7(1), 2001, pp. 30-37
7. Brinkmann, U; Keppler-Hafkemeyer, A; Hafkemeyer, P
   Recombinant immunotoxins for cancer therapy
   EXPERT OPINION ON BIOLOGICAL THERAPY
   
   U. Brinkmann et al., "Recombinant immunotoxins for cancer therapy", EXPERT OP B, 1(4), 2001, pp. 693-702
8. Alavi, JB; Eck, SL
   Gene therapy for high grade gliomas
   EXPERT OPINION ON BIOLOGICAL THERAPY
   
   J.B. Alavi e S.L. Eck, "Gene therapy for high grade gliomas", EXPERT OP B, 1(2), 2001, pp. 239-252
9. O'Hagan, DT; MacKichan, ML; Singh, M
   Recent developments in adjuvants for vaccines against infectious diseases
   BIOMOLECULAR ENGINEERING
   
   D.T. O'Hagan et al., "Recent developments in adjuvants for vaccines against infectious diseases", BIOMOL ENG, 18(3), 2001, pp. 69-85
10. Frenkel, GD; Caffrey, PB
    A prevention strategy for circumventing drug resistance in cancer chemotherapy
    CURRENT PHARMACEUTICAL DESIGN
    
    G.D. Frenkel e P.B. Caffrey, "A prevention strategy for circumventing drug resistance in cancer chemotherapy", CUR PHARM D, 7(16), 2001, pp. 1595-1614
11. Johnson, PWM
    The therapeutic use of antibodies for malignancy
    TRANSFUSION CLINIQUE ET BIOLOGIQUE
    
    P.W.M. Johnson, "The therapeutic use of antibodies for malignancy", TRANSF CL B, 8(3), 2001, pp. 255-259
12. Frankel, AE; Schuster, MW; Jurcic, JG
    Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia
    BIODRUGS
    
    A.E. Frankel et al., "Novel therapeutics for chemotherapy-resistant acute myeloid leukaemia", BIODRUGS, 15(1), 2001, pp. 55-71
13. Coze, C; Leimig, T; Jimeno, MT; Mannoni, P
    Retrovirus-mediated gene transfer of the cytokine genes interleukin-1 betaand tumor necrosis factor-alpha into human neuroblastoma cells: consequences for cell line behavior and immunomodulatory properties
    EUROPEAN CYTOKINE NETWORK
    
    C. Coze et al., "Retrovirus-mediated gene transfer of the cytokine genes interleukin-1 betaand tumor necrosis factor-alpha into human neuroblastoma cells: consequences for cell line behavior and immunomodulatory properties", EUR CYTOKIN, 12(1), 2001, pp. 78-86
14. Dalakas, MC
    Peripheral neuropathy and antiretroviral drugs
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
    
    M.C. Dalakas, "Peripheral neuropathy and antiretroviral drugs", J PERIPH N, 6(1), 2001, pp. 14-20
15. Buchsbaum, DJ; Curiel, DT
    Gene therapy for the treatment of cancer
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    
    D.J. Buchsbaum e D.T. Curiel, "Gene therapy for the treatment of cancer", CANC BIO R, 16(4), 2001, pp. 275-288
16. Crombet, T; Torres, O; Neninger, E; Catala, M; Rodriguez, N; Ramos, M; Fernandez, E; Iznaga, N; Perez, R; Lage, A
    Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    
    T. Crombet et al., "Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor", CANC BIO R, 16(1), 2001, pp. 93-102
17. Margolin, K; Synold, T; Longmate, J; Doroshow, JH
    Methodologic guidelines for the design of high-dose chemotherapy regimens
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    
    K. Margolin et al., "Methodologic guidelines for the design of high-dose chemotherapy regimens", BIOL BLOOD, 7(8), 2001, pp. 414-432
18. Khan, SA; Gaa, B; Pollock, BH; Shea, B; Reddy, V; Wingard, YR; Moreb, JS
    Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    
    S.A. Khan et al., "Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival", BIOL BLOOD, 7(8), 2001, pp. 433-438
19. Friedberg, JW; Neuberg, D; Monson, J; Jallow, H; Nadler, LM; Freedman, AS
    The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    
    J.W. Friedberg et al., "The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma", BIOL BLOOD, 7(8), 2001, pp. 446-453
20. Somlo, G; Chow, W; Hamasaki, V; Leong, L; Margolin, K; Morgan, R; Sniecinski, I; Frankel, P; Reardon, D; Longmate, J; Raschko, J; Shibata, S; O'Donnell, M; Smith, E; Tetef, M; Forman, S; Yen, Y; Molina, A; Doroshow, JH
    Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    
    G. Somlo et al., "Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies", BIOL BLOOD, 7(5), 2001, pp. 284-293
21. Kirn, D; Martuza, RL; Zwiebel, J
    Replication-selective virotherapy for cancer: Biological principles, risk management and future directions
    NATURE MEDICINE
    
    D. Kirn et al., "Replication-selective virotherapy for cancer: Biological principles, risk management and future directions", NAT MED, 7(7), 2001, pp. 783-789
22. Anderson, CP; Seeger, RC; Satake, N; Monforte-Munoz, HL; Keshelava, N; Bailey, HH; Reynolds, CP
    Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    
    C.P. Anderson et al., "Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line", J PED H ONC, 23(8), 2001, pp. 500-505
23. Dillman, RO
    Monoclonal antibody therapy for lymphoma - An update
    CANCER PRACTICE
    
    R.O. Dillman, "Monoclonal antibody therapy for lymphoma - An update", CANCER PRAC, 9(2), 2001, pp. 71-80
24. Sereti, I; Lane, HC
    Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies
    CLINICAL INFECTIOUS DISEASES
    
    I. Sereti e H.C. Lane, "Immunopathogenesis of human immunodeficiency virus: Implications for immune-based therapies", CLIN INF D, 32(12), 2001, pp. 1738-1755
25. McGinn, CJ; Lawrence, TS
    Recent advances in the use of radio sensitizing nucleosides
    SEMINARS IN RADIATION ONCOLOGY
    
    C.J. McGinn e T.S. Lawrence, "Recent advances in the use of radio sensitizing nucleosides", SEM RAD ONC, 11(4), 2001, pp. 270-280
26. Berry, SE; Kinsella, TJ
    Targeting DNA mismatch repair for radiosensitization
    SEMINARS IN RADIATION ONCOLOGY
    
    S.E. Berry e T.J. Kinsella, "Targeting DNA mismatch repair for radiosensitization", SEM RAD ONC, 11(4), 2001, pp. 300-315
27. Chmura, SJ; Gupta, N; Advani, SJ; Kufe, DW; Weichselbaum, RR
    Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation
    SEMINARS IN RADIATION ONCOLOGY
    
    S.J. Chmura et al., "Prospects for viral-based strategies enhancing the anti-tumor effects of ionizing radiation", SEM RAD ONC, 11(4), 2001, pp. 338-345
28. Imperiale, MJ; Pass, HI; Sanda, MG
    Prospects for an SV40 vaccine
    SEMINARS IN CANCER BIOLOGY
    
    M.J. Imperiale et al., "Prospects for an SV40 vaccine", SEM CANC B, 11(1), 2001, pp. 81-85
29. Kianmanesh, A; Hackett, NR; Lee, JM; Kikuchi, T; Korst, RJ; Crystal, RG
    Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity
    HUMAN GENE THERAPY
    
    A. Kianmanesh et al., "Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity", HUM GENE TH, 12(17), 2001, pp. 2035-2049
30. Flaherty, KT; Stevenson, JP; O'Dwyer, PJ
    Antisense therapeutics: lessons from early clinical trials
    CURRENT OPINION IN ONCOLOGY
    
    K.T. Flaherty et al., "Antisense therapeutics: lessons from early clinical trials", CURR OPIN O, 13(6), 2001, pp. 499-505
31. Reff, ME; Heard, C
    A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    M.E. Reff e C. Heard, "A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications", CR R ONC H, 40(1), 2001, pp. 25-35
32. Goldenberg, DM
    The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    D.M. Goldenberg, "The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy", CR R ONC H, 39(1-2), 2001, pp. 195-201
33. DeNardo, GL; Juweid, ME; White, CA; Wiseman, GA; DeNardo, SJ
    Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    G.L. DeNardo et al., "Role of radiation dosimetry in radioimmunotherapy planning and treatment dosing", CR R ONC H, 39(1-2), 2001, pp. 203-218
34. Calderoni, A; Cerny, T
    Taxanes in lung cancer: a review with focus on the European experience
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    
    A. Calderoni e T. Cerny, "Taxanes in lung cancer: a review with focus on the European experience", CR R ONC H, 38(2), 2001, pp. 105-127
35. Shimizu, Y; Utsugi, K; Umezawa, S; Shimizu, K; Hasumi, K; Suzuki, M; Takaku, F
    Effect of human urinary macrophage colony-stimulating factor on the immunefunctions and the blood cell counts in patients with ovarian carcinoma receiving cytotoxic chemotherapy
    ONCOLOGY REPORTS
    
    Y. Shimizu et al., "Effect of human urinary macrophage colony-stimulating factor on the immunefunctions and the blood cell counts in patients with ovarian carcinoma receiving cytotoxic chemotherapy", ONCOL REP, 8(4), 2001, pp. 767-772
36. Farmer, JP; Montes, JL; Freeman, CR; Meagher-Villemure, K; Bond, MC; O'Gorman, AM
    Brainstem gliomas - A 10-year institutional review
    PEDIATRIC NEUROSURGERY
    
    J.P. Farmer et al., "Brainstem gliomas - A 10-year institutional review", PED NEUROS, 34(4), 2001, pp. 206-214
37. Mulvihlll, S; Warren, R; Venook, A; Adler, A; Randlev, B; Heise, C; Kirn, D
    Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial
    GENE THERAPY
    
    S. Mulvihlll et al., "Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial", GENE THER, 8(4), 2001, pp. 308-315
38. Antczak, C; Bauvois, B; Monneret, C; Florent, JC
    A new acivicin prodrug designed for tumor-targeted delivery
    BIOORGANIC & MEDICINAL CHEMISTRY
    
    C. Antczak et al., "A new acivicin prodrug designed for tumor-targeted delivery", BIO MED CH, 9(11), 2001, pp. 2843-2848
39. Antman, KH
    A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer
    EUROPEAN JOURNAL OF CANCER
    
    K.H. Antman, "A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer", EUR J CANC, 37(2), 2001, pp. 173-179
40. Brandes, AA; Lacombe, D; Vecht, C
    Future trends in the treatment of brain tumours
    EUROPEAN JOURNAL OF CANCER
    
    A.A. Brandes et al., "Future trends in the treatment of brain tumours", EUR J CANC, 37(18), 2001, pp. 2297-2301
41. Hoff, PM; Saad, ED; Ravandi-Kashani, F; Czerny, E; Pazdur, R
    Phase I trial of i.v. administered tirapazamine plus cyclophosphamide
    ANTI-CANCER DRUGS
    
    P.M. Hoff et al., "Phase I trial of i.v. administered tirapazamine plus cyclophosphamide", ANTI-CANC D, 12(6), 2001, pp. 499-503
42. Sonneveld, P
    Multidrug resistance in haematological malignancies (Reprinted from Journal of Internal Medicine, vol 247, pg 521-534, 2000)
    JOURNAL OF INTERNAL MEDICINE
    
    P. Sonneveld, "Multidrug resistance in haematological malignancies (Reprinted from Journal of Internal Medicine, vol 247, pg 521-534, 2000)", J INTERN M, 249, 2001, pp. 47-60
43. Baumhakel, M; Kasel, D; Rao-Schymanski, RA; Bocker, R; Beckurts, KT; Zaigler, M; Barthold, D; Fuhr, U
    Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    
    M. Baumhakel et al., "Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes", INT J CL PH, 39(12), 2001, pp. 517-528
44. Maleniak, TC; Darling, JL; Lowenstein, PR; Castro, MG
    Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell deathin primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU
    CANCER GENE THERAPY
    
    T.C. Maleniak et al., "Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell deathin primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU", CANC GENE T, 8(8), 2001, pp. 589-598
45. Bollard, CM; Heslop, HE; Brenner, MK
    Gene-marking studies of hematopoietic cells
    INTERNATIONAL JOURNAL OF HEMATOLOGY
    
    C.M. Bollard et al., "Gene-marking studies of hematopoietic cells", INT J HEMAT, 73(1), 2001, pp. 14-22
46. Kern, W; Beckert, B; Lang, N; Stemmler, J; Beykirch, M; Stein, J; Goecke, E; Waggershauser, T; Braess, J; Schalhorn, A; Hiddemann, W
    Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer
    ANNALS OF ONCOLOGY
    
    W. Kern et al., "Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer", ANN ONCOL, 12(5), 2001, pp. 599-603
47. Kornblith, AB; Herndon, JE; Zuckerman, E; Godley, PA; Savarese, D; Vogelzang, NJ; Holland, JC
    The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study
    ANNALS OF ONCOLOGY
    
    A.B. Kornblith et al., "The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study", ANN ONCOL, 12(5), 2001, pp. 633-641
48. Tate, J; Olencki, T; Finke, J; Kottke-Marchant, K; Rybicki, LA; Bukowski, RM
    Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects
    ANNALS OF ONCOLOGY
    
    J. Tate et al., "Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects", ANN ONCOL, 12(5), 2001, pp. 655-659
49. Pfreundschuh, M; Hasenclever, D; Loeffler, M; Ehninger, G; Schmitz, N; Kirchner, H; Koch, P; Lathan, B; Rueffer, U; Sextro, M; Franklin, J; Tesch, H; Diehl, V
    Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF
    ANNALS OF ONCOLOGY
    
    M. Pfreundschuh et al., "Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF", ANN ONCOL, 12(4), 2001, pp. 471-477
50. Hidalgo, M; Eckhardt, SG
    Matrix metalloproteinase inhibitors: How can we optimize their development?
    ANNALS OF ONCOLOGY
    
    M. Hidalgo e S.G. Eckhardt, "Matrix metalloproteinase inhibitors: How can we optimize their development?", ANN ONCOL, 12(3), 2001, pp. 285-287
51. Rothenberg, ML; Kuhn, JG; Schaaf, LJ; Rodriguez, GI; Eckhardt, SG; Villalona-Calero, MA; Rinaldi, DA; Hammond, LA; Hodges, S; Sharma, A; Elfring, GL; Petit, RG; Locker, PK; Miller, LL; von Hoff, DD
    Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks
    ANNALS OF ONCOLOGY
    
    M.L. Rothenberg et al., "Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks", ANN ONCOL, 12(11), 2001, pp. 1631-1641
52. Wasserman, TH; Brizel, DM
    The role of amifostine as a radioprotector
    ONCOLOGY-NEW YORK
    
    T.H. Wasserman e D.M. Brizel, "The role of amifostine as a radioprotector", ONCOLOGY-NY, 15(10), 2001, pp. 1349-1354
53. Bernstein, ML; Reaman, GH; Hirschfeld, S
    Developmental therapeutics in childhood cancer - A perspective from the Children's Oncology Group and the US Food and Drug Administration
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    
    M.L. Bernstein et al., "Developmental therapeutics in childhood cancer - A perspective from the Children's Oncology Group and the US Food and Drug Administration", HEMAT ONCOL, 15(4), 2001, pp. 631
54. Perentesis, JP; Sievers, EL
    Targeted therapies for high-risk acute myeloid leukemia
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    
    J.P. Perentesis e E.L. Sievers, "Targeted therapies for high-risk acute myeloid leukemia", HEMAT ONCOL, 15(4), 2001, pp. 677
55. Rousseau, RF; Hirschmann-Jax, C; Takahashi, S; Brenner, MK
    Cancer vaccines
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    
    R.F. Rousseau et al., "Cancer vaccines", HEMAT ONCOL, 15(4), 2001, pp. 741
56. Pilati, P; Rossi, CR; Mocellin, S; Foletto, M; Scagnet, B; Pasetto, L; Lise, M
    Multimodal treatment of peritoneal carcinomatosis and sarcomatosis
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    
    P. Pilati et al., "Multimodal treatment of peritoneal carcinomatosis and sarcomatosis", EUR J SUR O, 27(2), 2001, pp. 125-134
57. Flanagan, DL; Gross, R; Jennings, CD; Caywood, BE; Goes, S; Kaplan, AM; Bryson, JS
    Induction of syngeneic graft-versus-host disease in LPS hyporesponsive C3H/HeJ mice
    JOURNAL OF LEUKOCYTE BIOLOGY
    
    D.L. Flanagan et al., "Induction of syngeneic graft-versus-host disease in LPS hyporesponsive C3H/HeJ mice", J LEUK BIOL, 70(6), 2001, pp. 873-880
58. Apisarnthanarax, N; Duvic, M
    Cutaneous T-cell lymphoma - New immunomodulators
    DERMATOLOGIC CLINICS
    
    N. Apisarnthanarax e M. Duvic, "Cutaneous T-cell lymphoma - New immunomodulators", DERM CLIN, 19(4), 2001, pp. 737
59. Curtin, JP; Blessing, JA; Webster, KD; Rose, PG; Mayer, AR; Fowler, WC; Malfetano, JH; Alvarez, RD
    Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study
    JOURNAL OF CLINICAL ONCOLOGY
    
    J.P. Curtin et al., "Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A Gynecologic Oncology Group Study", J CL ONCOL, 19(5), 2001, pp. 1275-1278
60. Sunwoo, JB; Herscher, LL; Kroog, GS; Thomas, GR; Ondrey, FG; Duffey, DC; Solomon, BI; Boss, C; Albert, PS; McCullugh, L; Rudy, S; Muir, C; Zhai, S; Figg, WD; Cook, JA; Mitchell, JB; Van Waes, C
    Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    J.B. Sunwoo et al., "Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer", J CL ONCOL, 19(3), 2001, pp. 800-811
61. Kurzrock, R; Cortes, J; Thomas, DA; Jeha, S; Pilat, S; Talpaz, M
    Pilot study of low-dose interleukin-11 in patients with bone marrow failure
    JOURNAL OF CLINICAL ONCOLOGY
    
    R. Kurzrock et al., "Pilot study of low-dose interleukin-11 in patients with bone marrow failure", J CL ONCOL, 19(21), 2001, pp. 4165-4172
62. Cheson, BD
    Some like it hot!
    JOURNAL OF CLINICAL ONCOLOGY
    
    B.D. Cheson, "Some like it hot!", J CL ONCOL, 19(19), 2001, pp. 3908-3911
63. Lee, P; Wang, F; Kuniyoshi, J; Rubio, V; Stuges, T; Groshen, S; Gee, C; Lau, R; Jeffery, G; Margolin, K; Marty, V; Weber, J
    Effects of interleukin-12 on the immune response to a multipeptide vaccinefor resected metastatic melanoma
    JOURNAL OF CLINICAL ONCOLOGY
    
    P. Lee et al., "Effects of interleukin-12 on the immune response to a multipeptide vaccinefor resected metastatic melanoma", J CL ONCOL, 19(18), 2001, pp. 3836-3847
64. Regine, WF; Valentino, J; Arnold, SM; Haydon, RC; Sloan, D; Kenady, D; Strottmann, J; Pulmano, C; Mohiuddin, M
    High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck
    JOURNAL OF CLINICAL ONCOLOGY
    
    W.F. Regine et al., "High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck", J CL ONCOL, 19(14), 2001, pp. 3333-3339
65. Kelly, WK; Curley, T; Slovin, S; Heller, G; McCaffrey, J; Bajorin, D; Ciolino, A; Regan, K; Schwartz, M; Kantoff, P; George, D; Oh, W; Smith, M; Kaufman, D; Small, EJ; Schwartz, L; Larson, S; Tong, W; Scher, H
    Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
    JOURNAL OF CLINICAL ONCOLOGY
    
    W.K. Kelly et al., "Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer", J CL ONCOL, 19(1), 2001, pp. 44-53
66. Korn, EL; Arbuck, SG; Pluda, JM; Simon, R; Kaplan, RS; Christian, MC
    Clinical trial designs for cytostatic agents: Are new approaches needed?
    JOURNAL OF CLINICAL ONCOLOGY
    
    E.L. Korn et al., "Clinical trial designs for cytostatic agents: Are new approaches needed?", J CL ONCOL, 19(1), 2001, pp. 265-272
67. Saha, S; Mondal, S
    Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
    
    S. Saha e S. Mondal, "Suppression of Ehrlich subcutaneous solid tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype antibody", J EXP CL C, 20(1), 2001, pp. 75-84
68. Akiyama, Y; Ohe, Y; Tamura, T; Sawada, M; Inoue, A; Kusaba, H; Yamamoto, N; Sekine, I; Kunitoh, H; Kodama, T; Saijo, N
    A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    
    Y. Akiyama et al., "A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer", JPN J CLIN, 31(10), 2001, pp. 482-487
69. Okada, S; Ueno, H; Okusaka, T; Ikeda, M; Furuse, J; Maru, Y
    Phase I trial of gemcitabine in patients with advanced pancreatic cancer
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    
    S. Okada et al., "Phase I trial of gemcitabine in patients with advanced pancreatic cancer", JPN J CLIN, 31(1), 2001, pp. 7-12
70. Xu, S; Zakian, K; Thaler, H; Matei, C; Alfleri, A; Chen, YC; Koutcher, JA
    Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    
    S. Xu et al., "Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity", INT J RAD O, 49(5), 2001, pp. 1381-1390
71. Kornek, GV; Potter, R; Selzer, E; Schratter, A; Ulrich-Pur, H; Rogy, M; Kraus, G; Scheithauer, W
    Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    
    G.V. Kornek et al., "Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine", INT J RAD O, 49(3), 2001, pp. 665-671
72. Mehta, M; Scrimger, R; Mackie, R; Paliwal, B; Chappell, R; Fowler, J
    A new approach to dose escalation in non-small-cell lung cancer
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    
    M. Mehta et al., "A new approach to dose escalation in non-small-cell lung cancer", INT J RAD O, 49(1), 2001, pp. 23-33
73. Koch, CJ; Hahn, SM; Rockwell, K; Covey, JM; McKenna, WG; Evans, SM
    Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitrolmidazoles
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    C.J. Koch et al., "Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitrolmidazoles", CANC CHEMOT, 48(3), 2001, pp. 177-187
74. Edelman, MJ; Quam, H; Mullins, B
    Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    M.J. Edelman et al., "Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines", CANC CHEMOT, 48(2), 2001, pp. 141-144
75. Witzig, TE
    Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    T.E. Witzig, "Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma", CANC CHEMOT, 48, 2001, pp. S91-S95
76. Fyfe, D; Price, C; Langley, RE; Pagonis, C; Houghton, J; Osborne, L; Woll, PJ; Gardner, C; Baguley, BC; Carmichael, J
    A phase I trial of amsalog (Cl-921) administered by intravenous infusion using a 5-day schedule
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    D. Fyfe et al., "A phase I trial of amsalog (Cl-921) administered by intravenous infusion using a 5-day schedule", CANC CHEMOT, 47(4), 2001, pp. 333-337
77. Papadopoulos, KP; Egorin, MJ; Huang, M; Troxel, AB; Kaufman, E; Balmaceda, CM; Vahdat, LT; Hesdorffer, CS
    The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer
    CANCER CHEMOTHERAPY AND PHARMACOLOGY
    
    K.P. Papadopoulos et al., "The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer", CANC CHEMOT, 47(1), 2001, pp. 45-50
78. Nakamura, K; Tanaka, Y; Shitara, K; Hanai, N
    Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    K. Nakamura et al., "Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions", CANCER IMMU, 50(5), 2001, pp. 275-284
79. Postema, EJ; Boerman, OC; Oyen, WJG; Raemaekers, JMM; Corstens, FHM
    Radioimmunotherapy of B-cell non-Hodgkin's lymphoma
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE
    
    E.J. Postema et al., "Radioimmunotherapy of B-cell non-Hodgkin's lymphoma", EUR J NUCL, 28(11), 2001, pp. 1725-1735
80. Tran, JQ; Gerber, LG; Kerr, BM
    Delavirdine - Clinical pharmacokinetics and drug interactions
    CLINICAL PHARMACOKINETICS
    
    J.Q. Tran et al., "Delavirdine - Clinical pharmacokinetics and drug interactions", CLIN PHARMA, 40(3), 2001, pp. 207-226
81. Antman, KH
    Randomized trials of high dose chemotherapy for breast cancer
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
    
    K.H. Antman, "Randomized trials of high dose chemotherapy for breast cancer", BBA-REV CAN, 1471(3), 2001, pp. M89-M98
82. Scott, CL; Robb, L; Nandurkar, HH; Mansfield, R; Alexander, WS; Begley, CG
    Thrombopoietin signaling is required for in vivo expansion of IL-11-responsive hematopoietic progenitor cells in the steady state
    EXPERIMENTAL HEMATOLOGY
    
    C.L. Scott et al., "Thrombopoietin signaling is required for in vivo expansion of IL-11-responsive hematopoietic progenitor cells in the steady state", EXP HEMATOL, 29(2), 2001, pp. 138-145
83. Kouroussis, C; Kakolyris, S; Mavroudis, D; Androulakis, N; Kalbakis, K; Agelaki, S; Sarra, E; Souglakos, J; Christodoulakis, M; Samonis, G; Georgoulias, V
    A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    
    C. Kouroussis et al., "A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors", AM J CL ONC, 24(4), 2001, pp. 404-407
84. Matheny, CJ; Lamb, MW; Brouwer, KLR; Pollack, GM
    Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation
    PHARMACOTHERAPY
    
    C.J. Matheny et al., "Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation", PHARMACOTHE, 21(7), 2001, pp. 778-796
85. Flinn, IW; Lazarus, HM
    Monoclonal antibodies and autologous stem cell transplantation for lymphoma
    BONE MARROW TRANSPLANTATION
    
    I.W. Flinn e H.M. Lazarus, "Monoclonal antibodies and autologous stem cell transplantation for lymphoma", BONE MAR TR, 27(6), 2001, pp. 565-569
86. Moingeon, P; Haensler, J; Lindberg, A
    Towards the rational design of Th1 adjuvants
    VACCINE
    
    P. Moingeon et al., "Towards the rational design of Th1 adjuvants", VACCINE, 19(31), 2001, pp. 4363-4372
87. Moingeon, P
    Cancer vaccines
    VACCINE
    
    P. Moingeon, "Cancer vaccines", VACCINE, 19(11-12), 2001, pp. 1305-1326
88. Ridwelski, K; Meyer, F
    Current options for palliative treatment in patients with pancreatic cancer
    DIGESTIVE DISEASES
    
    K. Ridwelski e F. Meyer, "Current options for palliative treatment in patients with pancreatic cancer", DIGEST DIS, 19(1), 2001, pp. 63-75
89. Habrand, JL; De Crevoisier, R
    Radiation therapy in the management of childhood brain tumors
    CHILDS NERVOUS SYSTEM
    
    J.L. Habrand e R. De Crevoisier, "Radiation therapy in the management of childhood brain tumors", CHILD NERV, 17(3), 2001, pp. 121-133
90. Cheng, AL; Hsu, CH; Lin, JK; Hsu, MM; Ho, YF; Shen, TS; Ko, JY; Lin, JT; Lin, BR; Wu, MS; Yu, HS; Jee, SH; Chen, GS; Chen, TM; Chen, CA; Lai, MK; Pu, YS; Pan, MH; Wang, YJ; Tsai, CC; Hsieh, CY
    Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions
    ANTICANCER RESEARCH
    
    A.L. Cheng et al., "Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions", ANTICANC R, 21(4B), 2001, pp. 2895-2900
91. Hsu, CH; Chen, J; Wu, CY; Cheng, AL; Pu, YS
    Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma
    ANTICANCER RESEARCH
    
    C.H. Hsu et al., "Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma", ANTICANC R, 21(1B), 2001, pp. 711-715
92. Hofer, S; Herrmann, R
    Chemotherapy for malignant brain tumors of astrocytic and oligodendrogliallineage
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    
    S. Hofer e R. Herrmann, "Chemotherapy for malignant brain tumors of astrocytic and oligodendrogliallineage", J CANC RES, 127(2), 2001, pp. 91-95
93. Gajra, A; Mehdi, SA; Kirshner, J; Newman, N; Graziano, SL
    Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma
    LUNG CANCER
    
    A. Gajra et al., "Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma", LUNG CANC, 32(2), 2001, pp. 189-196
94. Phan, TP; Crane, CH; Janjan, NA; Vrdoljak, E; Milas, L; Mason, KA
    WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment
    INTERNATIONAL JOURNAL OF PANCREATOLOGY
    
    T.P. Phan et al., "WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment", INT J PANCR, 29(1), 2001, pp. 19-23
95. Nishikawa, Y; Iwata, A; Katsumata, A; Xuan, XN; Nagasawa, H; Igarashi, I; Fujisaki, K; Otsuka, H; Mikami, T
    Expression of canine interferon-gamma by a recombinant vaccinia virus and its antiviral effect
    VIRUS RESEARCH
    
    Y. Nishikawa et al., "Expression of canine interferon-gamma by a recombinant vaccinia virus and its antiviral effect", VIRUS RES, 75(2), 2001, pp. 113-121
96. van Zuylen, L; Verweij, J; Sparreboom, A
    Role of formulation vehicles in taxane pharmacology
    INVESTIGATIONAL NEW DRUGS
    
    L. van Zuylen et al., "Role of formulation vehicles in taxane pharmacology", INV NEW DR, 19(2), 2001, pp. 125-141
97. Holst-Hansen, C; Low, JA; Stephens, RW; Johnson, MD; Carmeliet, P; Frandsen, TL; Brunner, N; Dickson, RB
    Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat
    BREAST CANCER RESEARCH AND TREATMENT
    
    C. Holst-Hansen et al., "Increased stromal expression of murine urokinase plasminogen activator in a human breast cancer xenograft model following treatment with the matrix metalloprotease inhibitor, batimastat", BREAST CANC, 68(3), 2001, pp. 225-237
98. Kintzel, PE
    Anticancer drug-induced kidney disorders - Incidence, prevention and management
    DRUG SAFETY
    
    P.E. Kintzel, "Anticancer drug-induced kidney disorders - Incidence, prevention and management", DRUG SAFETY, 24(1), 2001, pp. 19-38
99. Tan, AR; Swain, SM
    Novel agents: Clinical trial design
    SEMINARS IN ONCOLOGY
    
    A.R. Tan e S.M. Swain, "Novel agents: Clinical trial design", SEMIN ONCOL, 28(5), 2001, pp. 148-153
100. Oh, WK; George, DJ; Kaufman, DS; Moss, K; Smith, MR; Richie, JP; Kantoff, PW
     Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report
     SEMINARS IN ONCOLOGY
     
     W.K. Oh et al., "Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report", SEMIN ONCOL, 28(4), 2001, pp. 40-44